|
|
Related News
Four-year data suggest the CYPHER® stent provides long-term efficacy and safety benefits
EurekAlert! - Mar 13 1:51 PM ATLANTA -- March 11, 2006 - Patients treated with the CYPHER® Sirolimus-eluting Coronary Stent continued to experience significantly better long-term clinical outcomes than those who received a bare metal stent (BMS), according to data presented today during a symposium at the 2006 American College of Cardiology Scientific Session.
Brigham and Women's Cardiac Group Finds Enoxaparin Strategy is Better Than Commonly Administered Blo
Antara News - Mar 14 7:44 PM Doctors treating patients who have suffered an acute heart attack can now employ a better, more effective blood thinning strategy, using a medication called enoxaparin, to prevent blood clots from reforming in heart arteries.
Brigham and Women's Cardiac Group Finds Enoxaparin Strategy is Better Than Commonly Administered Blood Thinning
RedNova - Mar 14 11:15 AM BOSTON, Massachusetts, March 14 /PRNewswire-Fi
Brigham and Women's Cardiac Group Finds Enoxaparin Strategy is Better Than Commonly Administered Blood Thinning
[Press Release] PR Newswire via Yahoo! Finance - Mar 14 9:47 AM -
New Data Suggest Patients With Bifurcation Lesions Experienced Very Low Serious Event Rates With The CYPHER(R)
[Press Release] PR Newswire via Yahoo! Finance - Mar 13 1:22 PM Patients with bifurcated lesions, which are lesions that are spread into two parts at a common vessel juncture and are often difficult to treat, experienced a low rate of serious events at six-months with the CYPHER® Sirolimus-eluting Coronary Stent regardless of the stenting strategy, according to new multi-center, randomized clinical trial data presented today at the 2006 American College of
|
|
Top Related Terms
|
|
|
